V. Sandor

3.2k total citations
14 papers, 736 citations indexed

About

V. Sandor is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, V. Sandor has authored 14 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in V. Sandor's work include Colorectal Cancer Treatments and Studies (5 papers), Melanoma and MAPK Pathways (3 papers) and Synthesis of Tetrazole Derivatives (2 papers). V. Sandor is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Melanoma and MAPK Pathways (3 papers) and Synthesis of Tetrazole Derivatives (2 papers). V. Sandor collaborates with scholars based in United States, Spain and Netherlands. V. Sandor's co-authors include Susan E. Bates, Mikhail V. Blagosklonny, Susan D. Mertins, Dan L. Sackett, Edward A. Sausville, Adrian M. Senderowicz, Pim Brouwers, N Patronas, John D. Heiss and Richard H. Simon and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

V. Sandor

14 papers receiving 723 citations

Peers

V. Sandor

GENET

PFM

ONCOL

NEURO

Jennifer Lauchle United States

Monica Ceccon Italy

Michael Voralia Canada

Xiaosheng Fang China

J Lyons Germany

Gabriele Stefanzl Austria

Jennifer E. Amengual United States

Carla B. Ripamonti Italy

David Masiello United States

Maria Stella Pennisi Italy

Jennifer Lauchle United States

V. Sandor

512 ×1.3

181 ×0.6

GENET

83 ×0.4

PFM

203 ×1.1

ONCOL

104 ×0.6

NEURO

Citations per year, relative to V. Sandor V. Sandor (= 1×) peers Jennifer Lauchle

Countries citing papers authored by V. Sandor

Since Specialization

Citations

This map shows the geographic impact of V. Sandor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Sandor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Sandor more than expected).

Fields of papers citing papers by V. Sandor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Sandor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Sandor. The network helps show where V. Sandor may publish in the future.

Co-authorship network of co-authors of V. Sandor

This figure shows the co-authorship network connecting the top 25 collaborators of V. Sandor. A scholar is included among the top collaborators of V. Sandor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Sandor. V. Sandor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Kopetz, Scott, Axel Grothey, Eric Van Cutsem, et al.. (2019). BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. Annals of Oncology. 30. iv154–iv154. 14 indexed citations

Grisham, Rachel N., Susana Banerjee, Knut Mai, et al.. (2019). 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. A1.1–A1. 14 indexed citations

Dummer, Reinhard, Paolo A. Ascierto, Helen Gogas, et al.. (2017). Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Annals of Oncology. 28. v429–v430. 29 indexed citations

Gogas, Helen, Reinhard Dummer, Paolo A. Ascierto, et al.. (2017). Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. Annals of Oncology. 28. v442–v442. 1 indexed citations

Arance, Ana, Reinhard Dummer, Paolo A. Ascierto, et al.. (2017). Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. Annals of Oncology. 28. v441–v441. 7 indexed citations

Tabernero, Josep, Robin M.J.M. van Geel, Tormod Kyrre Guren, et al.. (2016). O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results. Annals of Oncology. 27. ii127–ii127. 5 indexed citations

Vannucchi, Alessandro M., H. Kantarjian, Jean‐Jacques Kiladjian, et al.. (2015). A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 100(9). 1139–1145. 164 indexed citations

Hurwitz, H., Nikhil Uppal, J. C. Bendell, et al.. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 25. ii115–ii115. 2 indexed citations

Verstovšek, Srđan, Ruben A. Mesa, Jason Gotlib, et al.. (2011). Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).. Journal of Clinical Oncology. 29(15_suppl). 6500–6500. 25 indexed citations

10.

Stinson, Sherman F., David Melnychuk, V. Sandor, et al.. (2003). SarCNU, a Nitrosourea Analog on a Day 1, 5, and 9 Oral Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 21(2). 232–240. 5 indexed citations

11.

Sandor, V., Adrian M. Senderowicz, Susan D. Mertins, et al.. (2000). P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. British Journal of Cancer. 83(6). 817–825. 250 indexed citations

12.

Sandor, V., E Reed, Gisele Sarosy, et al.. (1999). Synchronous inflammatory breast cancer and advanced ovarian carcinoma: A case with prolonged disease-free survival. Annals of Oncology. 10(5). 585–588. 1 indexed citations

13.

Benito, Marina Álvarez, Robert W. Robey, V. Sandor, et al.. (1998). Using the National Cancer Institute Anticancer Drug Screen to Assess the Effect of MRP Expression on Drug Sensitivity Profiles. Molecular Pharmacology. 54(5). 802–814. 46 indexed citations

14.

Sandor, V., Deborah A. Pearson, Scott M. Whitcup, et al.. (1998). Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.. Journal of Clinical Oncology. 16(9). 3000–3006. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact